AFP and hepatocellular carcinoma: To date, alpha-fetoprotein (AFP) is the only phase 5 biomarker (cancer control; the impact of screening on reducing the burden of disease in the population is quantified) approved for the surveillance and diagnosis of HCC in combination with ultrasonography for the former and multiphasic computed tomography or magnetic resonance imaging in the latter.